Company: CRL
Filing Date: 2025-01-14
Form Type: 8-K
Source: 0001100682-25-000003
Chunk: 2

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-01-14
Form: 8-K
Item: Item 7.01
Chunk 2
---
 trends or that are not statements of historical matters. These statements also include statements regarding: our future financial performance and drivers thereof (including, without limitation, revenue and revenue growth rates, operating income and margin, earnings per share, capital expenditures, operating and free cash flow, net interest expense, effective tax rate, foreign

exchange rates, corporate expenses, and leverage ratios) whether reported, constant currency, organic, and/or factoring acquisitions, with respect to Charles River as a whole and/or any of our reporting or operating segments or business units; our expectations with respect to the impact of external interest rate fluctuations; our annual guidance and longer-term targets, including the assumptions that form the basis for such guidance and targets; client demand, including our ability to increase client interest and the future demand for drug discovery, development, and CDMO and C& GT products and services; our expectations regarding stock repurchases and debt repayment; our business strategy, including with respect to capital deployment and leverage; our expectations regarding the financial performance of the companies we have acquired (including the impact of specific actions intended to cause related improvements, particularly with respect to our CDMO business); Charles River’s future performance as otherwise delineated in our forward-looking guidance; risks related to difficulties and delays inherent in the development, testing, approval, manufacturing, marketing and sale of cell and gene therapy products; and risks related to government regulation of the industries we participate in; and the impact of the events described herein on our financial results and our results of operations.

Forward-looking statements are based on the Company’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to, the impact of the events described herein on our financial results and our results of operations. Furthermore, these and other risks relating to the Company are set forth in the documents filed by Charles River with the Securities and Exchange Commission, including without limitation, the Risk Factors in the Company’s Annual Report on Form 10-K filed February 14, 2024 titled “ Failure to execute our business strategy could adversely impact our growth and profitability.”, “ Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business.”, “ Demand volatility and risk of credit losses from clients may adversely affect our business.”, “ Our Biologics Solutions business